Thomas M MacDonald
Overview
Explore the profile of Thomas M MacDonald including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
156
Citations
2949
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hellwig K, Magyari M, MacDonald T, Cesta C, Wergeland S, Leinonen M, et al.
Ther Adv Neurol Disord
. 2025 Jan;
18:17562864241310996.
PMID: 39872126
Background: Cladribine tablets are contraindicated during pregnancy; therefore, safety data on pregnancies exposed to this treatment are limited. CLEAR collects and describes pregnancy outcomes in this understudied population. Objectives: To...
2.
Vaja R, Ferreira P, Portas L, Ahmetaj-Shala B, Cypaite N, Gashaw H, et al.
Eur Heart J Open
. 2024 Dec;
4(6):oeae088.
PMID: 39660078
Aims: The Standard care vs. Celecoxib Outcome Trial (SCOT) found similar risk of cardiovascular events with traditional non-steroidal anti-inflammatory drugs (NSAIDs) and the cyclooxygenase-2-selective drug celecoxib. While pre-clinical work has...
3.
Major T, Takei R, Matsuo H, Leask M, Sumpter N, Topless R, et al.
Nat Genet
. 2024 Nov;
56(11):2577.
PMID: 39501129
No abstract available.
4.
Major T, Takei R, Matsuo H, Leask M, Sumpter N, Topless R, et al.
Nat Genet
. 2024 Oct;
56(11):2392-2406.
PMID: 39406924
Gout is a chronic disease that is caused by an innate immune response to deposited monosodium urate crystals in the setting of hyperuricemia. Here, we provide insights into the molecular...
5.
Copland R, Hanke S, Rogers A, Mpaltadoros L, Lazarou I, Zeltsi A, et al.
J Med Internet Res
. 2024 Sep;
26:e47882.
PMID: 39226549
Decentralized clinical trials (DCTs) are becoming increasingly popular. Digital clinical trial platforms are software environments where users complete designated clinical trial tasks, providing investigators and trial participants with efficient tools...
6.
McCallum L, Lip S, McConnachie A, Brooksbank K, MacIntyre I, Doney A, et al.
Hypertension
. 2024 Jul;
81(10):2049-2059.
PMID: 39077768
Background: UMOD (uromodulin) has been linked to hypertension through potential activation of Na-K-2Cl cotransporter (NKCC2), a target of loop diuretics. We posited that hypertensive patients carrying the rs13333226-AA genotype would...
7.
Pigazzani F, Dyar K, Morant S, Vetter C, Rogers A, Flynn R, et al.
EClinicalMedicine
. 2024 May;
72:102633.
PMID: 38774676
Background: Timing drug administration to endogenous circadian rhythms may enhance treatment efficacy. In the Chronotype sub-study of the Treatment in Morning versus Evening (TIME) clinical trial we examined whether timing...
8.
Mackenzie I, Hawkey C, Ford I, Greenlaw N, Pigazzani F, Rogers A, et al.
Health Technol Assess
. 2024 Mar;
28(18):1-55.
PMID: 38551218
Background: Allopurinol is a xanthine oxidase inhibitor that lowers serum uric acid and is used to prevent acute gout flares in patients with gout. Observational and small interventional studies have...
9.
Faconti L, Kulkarni S, Delles C, Kapil V, Lewis P, Glover M, et al.
J Hum Hypertens
. 2023 Nov;
38(1):8-18.
PMID: 37964158
Alongside the lack of homogeneity among international guidelines and consensus documents on primary hyperaldosteronism, the National UK guidelines on hypertension do not provide extensive recommendations regarding the diagnosis and management...
10.
Krzemien P, Kasperczyk S, Banach M, Kasperczyk A, Dobrakowski M, Tomasik T, et al.
Arch Med Sci
. 2023 Sep;
19(5):1214-1227.
PMID: 37732061
Introduction: Oxidative stress is one of many factors suspected to promote antinuclear autoantibody (ANA) formation. Reactive oxygen species can induce changes in the antigenic structure of macromolecules, causing the immune...